Prediction of early recurrence after radical resection for advanced gastric cancer
10.3760/cma.j.issn.1007-631X.2011.07.005
- VernacularTitle:进展期胃癌根治术后早期复发的危险因素分析
- Author:
Jingzhu ZHAO
;
Rupeng ZHANG
;
Gang WANG
;
Fangxuan LI
;
Xuejun WANG
;
Qiang XUE
;
Han LIANG
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Recurrence;
Risk factors;
Regression analysis
- From:
Chinese Journal of General Surgery
2011;26(7):549-552
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical features and prognosis of recurrent gastric cancer. Methods The clinical data of 147 patients with recurrent gastric cancer was reviewed. Risk factors correlated with tumor recurrence and recurrent intervals were studied by logistic regression analysis. Survival analyses and comparisons were performed using Kaplan-Meier plots, the log rank test and the Cox proportional hazards model. Results Patients were divided into an early recurrence group consisting of 86 patients (recurred within one year after surgery) and a late recurrence group of 61 patients (recurred one year or more after surgery). There were significant difference in size of primary tumor, Borrmann stage, type of gastrectomy, T stage, N stage, TNM stage between the two groups(P ＜0.05). Multivariate analysis showed that the TNM stage and N stage independently influenced the recurrent time ( P ＜ 0. 05 ). In univariate survival analysis, post-gastrectomy chemotherapy(P ＜0. 05) , T stage (P ＜0. 05) , N stage(P ＜0.01) , TNM stage ( P ＜ 0. 01) , recurrence-free interval (P ＜ 0. 01) and reoperation (P ＜ 0.01) were significantly correlated with the prognosis. In multivariable analysis, TNM stage(P ＜0. 01) , recurrence-free interval ( P ＜ 0. 05 ) and reoperation ( P ＜ 0. 05 ) were independent factors predicting recurrence. Conclusions The TNM stage and N stage were the important factors predicting the time of recurrence after curative resection for gastric cancer. Patients with recurrent gastric cancer have poor prognosis and reoperation was associated with an improved survival in patients with recurrent gastric cancer.
